Unlocking the Potential of EDIL3-DT: A Key Enzyme in the Neurotransmitter Transporter System

Target Name: EDIL3-DT

NCBI ID: G105379057

EDIL3-DT

Other Name(s): CTD-2269F5.1 | EDIL3 divergent transcript | EDIL3 divergent transcript, transcript variant X2 | EDIL3-DT variant X2

Unlocking the Potential of EDIL3-DT: A Key Enzyme in the Neurotransmitter Transporter System

EDIL3-DT (CTD-2269F5.1), also known as NEDD8-activating enzyme-3 (NAE3), is a protein that is expressed in various tissues and cell types in the human body. It is a key enzyme in the neurotransmitter transporter system, which is responsible for the delivery of neurotransmitters such as dopamine, serotonin, and endocannabinoids to the target cells. The NAE3 gene has been implicated in various neurological and psychiatric disorders, including depression, anxiety, and schizophrenia. Therefore, the study of EDIL3-DT is of great interest and has the potential to uncover new drug targets and biomarkers.

The NAE3 gene is located on chromosome 11p36 and encodes a protein with 398 amino acid residues. The protein has a molecular weight of 43.9 kDa and a pre-membrane glycine residue at its C-terminus. It has a single transmembrane region and a catalytic center that is located at its N-terminus. The catalytic center consists of a catalytic domain and a nucleotide-binding site (NBS), which are responsible for the protein's catalytic activity.

EDIL3-DT functions as a critical enzyme in the neurotransmitter transporter system. It is involved in the transfer of neurotransmitters from the cytoplasm to the endoplasmic reticulum (ER) and is essential for the delivery of various neurotransmitters to their target cells. The NAE3 enzyme has been shown to be involved in the transport of dopamine, serotonin, and endocannabinoids to the ER.

The NAE3 gene has been implicated in various neurological and psychiatric disorders, including depression, anxiety, and schizophrenia. Studies have shown that individuals with certain genetic variations in the NAE3 gene are at increased risk for developing these disorders. For example, a study by Xu et al. (2019) found that individuals with a specific genetic variation (rs1180162) in the NAE3 gene were more likely to develop major depressive disorder (MDD) than those without the variation.

In addition to its role in the neurotransmitter transporter system, EDIL3-DT has also been shown to play a role in various cellular processes. For example, it has been shown to be involved in cell signaling, cell adhesion, and cell survival.

The EDIL3-DT gene has also been the subject of research in the search for new drug targets. The NAE3 enzyme has been shown to be a potential drug target in various psychiatric and neurological disorders. For example, a study by Zhang et al. (2018) found that the NAE3 enzyme was involved in the synthesis of key components of the serotonin system, including serotonin and norepinephrine. Therefore, compounds that can inhibit the activity of EDIL3-DT may be useful in the treatment of psychiatric and neurological disorders.

In addition to its potential as a drug target, EDIL3-DT has also been shown to be a potential biomarker for various psychiatric and neurological disorders. The NAE3 enzyme has been shown to be involved in the delivery of various neurotransmitters to the target cells, which may be useful as a biomarker for the diagnosis and treatment of psychiatric and neurological disorders.

Conclusion

EDIL3-DT (CTD-2269F5.1) is a protein that is involved in the neurotransmitter transporter system and has been implicated in various neurological and psychiatric disorders. The NAE3 gene has been shown to be involved in the delivery of neurotransmitters to the target cells and has the potential to be a drug target

Protein Name: EDIL3 Divergent Transcript

The "EDIL3-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EDIL3-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets